Unbiased Analysis of Today's Healthcare Issues
A message from the Innovation and Value Initiative (IVI) Center for Innovation & Value Research CEO Jason Spangler. I was the former Director of Research at IVI and I wish them luck with the new name as they continue with their mission to “To advance the science, practice, and use of patient-centered Health Technology Assessment…
That is the subtitle title of a paper by Jansen, Incerti and Linthicum (2019) in Pharmacoeconomics. The Innovation and Value Initiative started the Open-Source Value Project with the aim to improve the credibility and relevance of model-based value assessment in the context of the US healthcare environment. As a core activity of the Open-Source Value…
Guest post by Mark Linthicum, Director of Scientific Communications at The Innovation and Value Initiative To get to Value Assessment 2.0, a concerted effort across fields of expertise is needed to improve methods and establish practical approaches that make sense in real-world decision making. The Innovation and Value Initiative’s Open-Source Value Project aims to catalyze…
My colleagues Jeroen Jansen, Devin Incerti along with Jeff Curtis think so. In JMCP they write: In the United States, there is an increased interest to understand the value of health technologies. Cost-effectiveness analysis is arguably the most appropriate framework to quantify value and to inform reimbursement decision making regarding medical interventions; however, a thorough…
IVI will be hosting two webinars introducing our new open-source value model in non-small cell lung cancer. Devin Incerti and Jeroen Jansen will lead the webinar tomorrow. Modernizing Models for Value Assessment: A Detailed Discussion of the Open-Source IVI-NSCLC Model Date: February 27, 2019 at 2:30 PM EST / 11:30 AM PST Content: In-depth discussion…
In a recently published paper in PharmacoEconomics, I–along with co-authors Devin Incerti, Jeff Curtis, Darius Lakdawalla, and Jeroen Jansen–describe a recently developed open-source platform for measuring the value of treatments for rheumatoid arthritis. The model itself is here, but and the abstract from Incerti et al. (2019) is below: Objective The nature of model-based cost-effectiveness…
Please see below some exciting news from the Innovation and Value Initiative (IVI) on the release of the IVI-NSCLC Value Tool. The press release is below. IVI is excited to publish our Open-Source Value Platform (OSVP) model focusing on epidermal growth factor receptor (EGFR) positive, non-squamous non-small cell lung cancer (NSCLC), and we invite public…
The Innovation and Value Initiative (IVI) where I serve as the Director of Research was recently in the news with a Journal of Clinical Pathways interview with Executive Director Jennifer Bright and Director of Scientific Communications Mark Linthicum. Some excerpts: Can you tell us about the Innovation and Value Initiative? Bright: We are working in three primary areas.…
The Innovation and Value Initiative today announced that it is in the process of releasing a new model and value tool to evaluate treatments for for EGFR-positive non-small cell lung cancer (NSCLC). More details on the model (named the IVI-NSCLC model) are available here, which includes a study protocol and model timeline. Oncology is an…
On November 8th, the Innovation and Value Initiative (IVI) launched a new effort to help redefine the way we measure value in health care: the Open-Source Value Project (OSVP). A first-of-its-kind effort that engages all health care stakeholders in an open process to advance the way we measure value in health care treatments and services,…